potentially serious concerns with Syk inhibitors pertaining to potential increases in breast cancer risk
I think that's too strongly put. This is very much a theoretical concern, and the work I cited remains very obscure. So it might come back to bite them many years from now, but I doubt it will have much impact on the stock price of any of the companies involved in the short/medium term.
Market Data 
Markets 
AI
